Adalimumab Biosimilar Trends and Forecast
The future of the global adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets. The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030 with a CAGR of 21.6% from 2024 to 2030. The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.
• Lucintel forecasts that, within the product category, exemptia is expected to witness the highest growth over the forecast period.
• Within the end use category, hospitals pharmacies is expected to remain the largest segment due to the fact that adalimumab biosimilars are used to treat a variety of autoimmune diseases, which are typically managed by specialists in hospital settings.
• In terms of regions, North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.
A more than 150-page report is developed to help in your business decisions.
Emerging Trends in the Adalimumab Biosimilar Market
The Adalimumab biosimilar market has become quite dynamic, driven by multiple emerging trends. These trends have reshaped the way biosimilars are developed, marketed, and adopted, and are transforming competition and market strategy globally. Understanding these trends is essential for stakeholders aiming to navigate the evolving landscape.
• Increased Competition in the Market: With many biosimilars entering the market, competition has increased, prices have dropped, and patient access has improved. This trend is evident worldwide, with several companies competing by offering differentiated products and strategic pricing. This growing competition is fostering innovation in biologic treatments, improving access for both providers and patients.
• Regulatory Flexibility: Regulatory bodies are increasingly adopting flexible approaches to facilitate the approval of biosimilars. For example, both the FDA and EMA have streamlined their approval pathways, enabling quicker market access. This will significantly enhance access to more affordable treatment options and create a more competitive market environment. Additional regulatory frameworks are expected to sustain the growth in biosimilar adoption.
• Focus on Patient Access and Affordability: There is growing focus on enhancing patient access through affordability initiatives involving biosimilars. Payers and healthcare systems are implementing policies, such as pricing negotiations and formulary inclusions, to promote the use of biosimilars. These measures aim to reduce treatment costs while improving access to essential therapies—an imperative for global healthcare.
• Greater Stringency in Clinical Data: As biosimilars gain prevalence, there is a shift toward requiring more robust clinical data to substantiate safety and efficacy. This trend arises from increased scrutiny by regulatory bodies and healthcare providers. In response, companies are investing in extensive clinical trials to meet these requirements, influencing development timelines and overall costs.
• Value-Based Pricing Model Adoption: The adoption of value-based pricing is becoming more common in the biosimilar market. In this model, the price of a product is based on the therapeutic value it provides. This approach aligns with efforts to improve cost-effectiveness and patient outcomes. Value-based pricing is expected to drive market dynamics by incentivizing the use of biosimilars and easing some of the economic burdens faced by healthcare systems.
Emerging trends in the adalimumab biosimilar market indicate a wave of increasing competition, innovation, and access. Developmental advancements in biosimilars will lead to higher-quality products with more streamlined regulatory pathways. A key trend in the market is cost reduction, with competitive pricing driving the entry of multiple biosimilars into the market.
Recent Developments in the Adalimumab Biosimilar Market
Recent developments in the Adalimumab biosimilar market have completely changed the face of biologic therapies. These developments reflect not only advancements in biosimilar technology but also changes in regulations and market dynamics. Understanding these key developments provides insight into the ways in which the market is evolving and what stakeholders can expect in the future.
• Humira Patent Expirations: When HumiraÄX%$%Xs patents expired in 2023, it marked a pivotal moment in the market for biosimilars. Many biosimilars began to enter the market, and with increasing competition, prices were driven down. Biosimilars such as Amesite and Hulin have been released, offering wider treatment options and greater accessibility to biologic therapies.
• Regulatory Approvals and Market Entry: Recently, various biosimilars of Adalimumab have gained regulatory approval for market entry. For example, the FDA approved drugs such as Amesite and MylanÄX%$%Xs Hulin, accelerating their availability. These approvals are crucial for increasing competition in the market and providing a wider range of options for both patients and healthcare providers.
• Pricing Strategies and Market Penetration: Biosimilars have entered the market with competitive pricing strategies to capture market share. Companies are adopting various pricing models, such as discounts and value-based pricing, to attract healthcare providers and payers. This trend is reshaping market dynamics and increasing the adoption of biosimilars.
• Rise in Clinical Trials: Clinical trials testing Adalimumab biosimilars for their safety and efficacy have increased. These trials are essential for regulatory approvals and help to address concerns about the performance of biosimilars compared to the reference product. More robust clinical data facilitates market entry and instills greater confidence among key stakeholders.
• Market Penetration into Emerging Economies: Biosimilars of Adalimumab are gaining rapid acceptance in emerging economies such as India and China. Local players are introducing more biosimilar products at affordable prices, and government policies encourage their use. This expansion highlights the growing global market and the increasing demand for cost-effective treatment solutions in these regions.
Recent developments in the Adalimumab biosimilar market are driving increased competition and access, with improvements in the quality of biosimilars and cost reduction. This will lead to better treatment options, higher market access, and benefits for both patients and health systems.
Strategic Growth Opportunities for Adalimumab Biosimilar Market
All strategic growth opportunities in different applications are key segments of the Adalimumab biosimilar market. A growing market is one where stakeholders realize significant opportunities for growth by responding to market demand and taking advantage of emerging trends. Key applications offer pronounced potential for growth and innovation.
• Market Expansion: Emerging Markets: Developing markets, especially in Asia and Latin America, will provide significant growth prospects for Adalimumab biosimilars. This can be enabled by increasing demand for more affordable biologics within these regions. Other strategies include forming local partnerships for manufacturing and adopting pricing models designed to improve market access and meet regional healthcare needs.
• Development of New Biosimilar Products: There are further opportunities in the development of new Adalimumab biosimilars with enhanced formulations or delivery methodologies. Product innovation may include extended-release formulations, combination therapies, or other forms that better meet patient needs. Investment in R&D for new biosimilar products can capture additional market share and drive further growth.
• Strategic Partnerships and Collaborations: Strategic partnerships between biosimilar manufacturers, healthcare providers, and payers can strengthen the market position of Adalimumab biosimilars. Collaboration agreements may take various forms, such as joint ventures, co-marketing agreements, and distribution partnerships. Such alliances can offer access to markets, increase product visibility, and smoothen the adoption curve for biosimilars.
• Integration into Health Systems: Formulary inclusion and guidelines that integrate biosimilars into established health systems will continue to drive adoption. It is also essential to engage with healthcare authorities to ensure that biosimilars are included in treatment protocols and reimbursement schedules. This integration will contribute to broader use and cost savings in healthcare systems.
• Patient Education: Investments in patient education and awareness programs present a growth opportunity. Educating patients about the benefits and safety of biosimilars can overcome resistance and improve acceptance. Effective communication strategies and educational campaigns will boost patient confidence and facilitate a smooth transition to biosimilars.
Strategic growth opportunities in the Adalimumab biosimilar market include expanding into emerging markets, leveraging cost advantages, and forming strategic partnerships. These opportunities will drive market expansion, enhance patient access, and foster innovation in biosimilar development.
Adalimumab Biosimilar Market Driver and Challenges
The market dynamics of Adalimumab biosimilars are influenced by technological, economic, and regulatory factors that contribute to market growth and present considerable challenges. Stakeholders will need to be aware of these drivers and challenges to cope effectively with the dynamically changing landscape. All these factors—technological advancements, economic pressures, and regulatory changes—together shape the market dynamics, affecting everything from development and approval to market adoption and competition.
The factors responsible for driving the Adalimumab biosimilar market include:
• Patent Expiration of Humira: The expiry of HumiraÄX%$%Xs patent in 2023 is considered a leading driver for the biosimilar market. It paved the way for many biosimilars to enter the market, creating a competitive environment that drives prices down and expands access to biologic treatments. A patent cliff stimulates investment in the development of biosimilars and broadens treatment options for patients.
• Cost-Effectiveness: The key driver for the adoption of biosimilars is that they offer a less expensive alternative to originator biologic therapies. Healthcare systems and payers are increasingly focused on reducing drug costs, and biosimilars provide significant savings compared with branded biologics. This cost advantage encourages wide adoption and integration into treatment regimens.
• Regulatory Support: The FDA, along with other agencies like the EMA, has established regulatory frameworks that enable the approval and market entry of Adalimumab biosimilars. Simplified approval processes, such as less elaborate clinical trials and more transparent guidelines, reduce obstacles to entry and accelerate their availability in the market.
• Increased Patient Demand: Growing patient demand for affordable, effective treatments is driving the adoption of biosimilars. As awareness of biosimilars rises, patients are increasingly seeking cost-saving treatments. This trend represents the general push toward more patient-centric and cost-efficient healthcare solutions.
• Pressure from the Healthcare System: There is mounting pressure on healthcare systems worldwide with respect to drug costs and access to treatments. Biosimilars provide a solution by offering similar therapeutic benefits at a lower cost. The economic burden on health budgets turns into a driver for the introduction of biosimilars, which help achieve cost savings while maintaining standards of treatment.
Challenges in the Adalimumab biosimilar market include:
• Regulatory Hurdles: Despite supportive frameworks, the approval processes for biosimilars may remain cumbersome and divergent across regions. Navigating various regulatory requirements and demonstrating equivalence to the originator biologic requires substantial investment in clinical trials and documentation. These regulatory barriers could delay market entry and increase development costs.
• Market Acceptance: Sluggish market acceptance is a challenge, with concerns about the efficacy and safety of biosimilars compared to their originator biologic counterparts. Due to unfamiliarity or perceived risks, physicians and patients may resist switching, which will impact the rate of adoption. These obstacles can be overcome with robust evidence and effective educational initiatives.
• Disputes over Intellectual Property: Intellectual property issues, including patent disputes and litigations, are significant challenges faced by biosimilar developers. Legal battles over exclusivity and patent rights can delay market entry and increase costs. These disputes must be negotiated cautiously with the right legal approach, as they can affect competitive dynamics in the market.
The drivers in the Adalimumab biosimilar market include patent expiration, cost-effectiveness, regulatory support, patient demand, and pressures from the healthcare system. On the other hand, challenges such as regulatory hurdles, market acceptance, and intellectual property disputes must be addressed. Together, these drivers and challenges influence market dynamics, affecting the rate of adoption, competition, and overall market growth. Capitalizing on these drivers will be key to overcoming the challenges.
List of Adalimumab Biosimilar Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies adalimumab biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adalimumab biosimilar companies profiled in this report include-
• Alfred E. Tiefenbacher
• Amgen
• Boehringer Ingelheim
• Glenmark
• Zydus
• Torrent Pharmaceuticals
• Reliance Life Sciences
Adalimumab Biosimilar by Segment
The study includes a forecast for the global adalimumab biosimilar by product, end use, and region.
Adalimumab Biosimilar Market by Product [Analysis by Value from 2018 to 2030]:
• Exemptia
• Adalirel
• Cipleumab
• Others
Adalimumab Biosimilar Market by End Use [Analysis by Value from 2018 to 2030]:
• Hospitals Pharmacies
• Retail Pharmacies
• Others
Adalimumab Biosimilar Market by Region [Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Adalimumab Biosimilar Market
In the wake of growing competition, changes in regulation, and evolving market dynamics, new and significant developments have been witnessed in the Adalimumab biosimilar market. With the expiration of patents for the original Adalimumab, commonly referred to as Humira, biosimilars are being introduced as more affordable options. As a result, this has affected pricing, market access, and treatment options across diverse regions. Market dynamics in each country have influenced the adoption and growth of these biosimilars, which are driven by the regulatory environment, healthcare infrastructure, and economic considerations.
• United States: With the expiration of HumiraÄX%$%Xs patent in 2023, the Adalimumab biosimilar market saw rapid growth in the U.S. Other biosimilars, such as AmgenÄX%$%Xs Amesite and AbbVieÄX%$%Xs Hulin, have entered the market with competitive pricing. Favorable FDA approvals, along with growing healthcare cost containment pressures, have underpinned the increased adoption of these biosimilars. They continue to gain significant market share, though payer and provider education remain challenges.
• China: The biosimilar market is growing in China, as the NMPA fast-tracks approvals for Adalimumab biosimilars. Companies like Innocents Biologics and Coheres Biosciences are making significant inroads into the country. Recent price negotiations and government initiatives to provide more affordable drugs to the population have contributed to this growth. However, broader market penetration remains restricted due to a lack of physician awareness and disparities in healthcare infrastructure across geographical regions.
• Germany: With its strong healthcare infrastructure and favorable regulatory environment, Germany has become one of the largest adopters of Adalimumab biosimilars in Europe. Recent developments include the increasing market share of biosimilars, such as BLAZIC, in the treatment of inflammatory diseases. The promotion of cost-effectiveness—achieved through competitive pricing—within the German healthcare system is driving the rising demand for biosimilars.
• India: The biosimilars market is developing in India, with growing interest from both domestic and international firms. Companies like Cadila Healthcare and Biocon have launched Adalimumab biosimilars for indications that leverage the large patient pool and expanding healthcare infrastructure. Recent government policies have made healthcare more affordable, with price cuts increasing access to the market. However, stronger regulatory challenges and variability in quality standards continue to constrain the market.
• Japan: Entries from companies such as Pfizer and Samsung Biologics are increasing the Japanese market for Adalimumab biosimilars. In response, the PMDA (Pharmaceuticals and Medical Devices Agency) has simplified the approval process, facilitating the adoption of biosimilars. However, the high standards for clinical data and resistance from some physicians have slowed growth. The Japanese market is showing consistent, if not stellar, growth in biosimilars, supported by cost pressures and healthcare reforms.
Features of the Global Adalimumab Biosimilar Market
Market Size Estimates: Adalimumab biosimilar market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Adalimumab biosimilar market size by product, end use, and region in terms of value ($B).
Regional Analysis: Adalimumab biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different products, end uses, and regions for the adalimumab biosimilar market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adalimumab biosimilar market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What is the adalimumab biosimilar market size?
Answer: The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030.
Q2. What is the growth forecast for adalimumab biosimilar market?
Answer: The global adalimumab biosimilar market is expected to grow with a CAGR of 21.6% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the adalimumab biosimilar market?
Answer: The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.
Q4. What are the major segments for adalimumab biosimilar market?
Answer: The future of the adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets.
Q5. Who are the key adalimumab biosimilar market companies?
Answer: Some of the key adalimumab biosimilar companies are as follows:
• Alfred E. Tiefenbacher
• Amgen
• Boehringer Ingelheim
• Glenmark
• Zydus
• Torrent Pharmaceuticals
• Reliance Life Sciences
Q6. Which adalimumab biosimilar market segment will be the largest in future?
Answer: Lucintel forecasts that exemptia is expected to witness the highest growth over the forecast period.
Q7. In adalimumab biosimilar market, which region is expected to be the largest in next 6 years?
Answer: North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the adalimumab biosimilar market by product (exemptia, adalirel, cipleumab, and others), end use (hospitals pharmacies, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Adalimumab Biosimilar Market, Adalimumab Biosimilar Market Size, Adalimumab Biosimilar Market Growth, Adalimumab Biosimilar Market Analysis, Adalimumab Biosimilar Market Report, Adalimumab Biosimilar Market Share, Adalimumab Biosimilar Market Trends, Adalimumab Biosimilar Market Forecast, Adalimumab Biosimilar Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.